The Febrile Neutropenia (FN) Market is fundamentally driven by the relentless increase in global cancer incidence and the associated use of cytotoxic chemotherapy. FN, a common and potentially life-threatening complication of chemotherapy, occurs when a patient develops a fever alongside a dangerously low neutrophil count, leaving them highly vulnerable to severe infection and sepsis. The...